Published in J Res Med Sci on March 01, 2013
Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med (1962) 22.33
Prostaglandins and leukotrienes: advances in eicosanoid biology. Science (2001) 11.23
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res (1988) 8.53
Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther (1953) 5.14
Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci (1984) 4.87
5-Hydroxytryptamine and histamine as mediators of the vascular injury produced by agents which damage mast cells in rats. J Exp Med (1956) 4.85
Biphasic development of carrageenin edema in rats. J Pharmacol Exp Ther (1969) 4.24
Pain measurement: an overview. Pain (1985) 3.54
Nonsteroidal antiinflammatory drugs--differences and similarities. N Engl J Med (1991) 3.05
Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci (1995) 3.00
Pharmacology of 2-amino-indane hydrochloride (Su-8629): a potent non-narcotic analgesic. J Pharmacol Exp Ther (1961) 1.99
Mediators of the inflammation induced in the rat paw by carrageenin. Br J Pharmacol (1971) 1.93
Pain modulation: expectation, opioid analgesia and virtual pain. Prog Brain Res (2000) 1.74
A modified plethysmographic apparatus for recording volume changes in the rat paw. J Pharm Pharmacol (1962) 1.56
Studies on the anti-inflammatory, antipyretic and analgesic properties of Alstonia boonei stem bark. J Ethnopharmacol (2000) 1.46
Tea and cancer prevention: studies in animals and humans. J Nutr (2003) 1.32
Arene ruthenium complexes as anticancer agents. Dalton Trans (2009) 1.29
Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis (2005) 1.22
Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res (1998) 1.22
A method for the evaluation of analgesic activity using rats. Br J Pharmacol Chemother (1946) 1.22
Developing new metal-based therapeutics: challenges and opportunities. Dalton Trans (2007) 1.13
The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models. Eur J Pharmacol (2000) 1.09
Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes. Biochemistry (1995) 1.07
Evaluation of anti-inflammatory activity of Vernonia cinerea Less. extract in rats. Phytomedicine (2003) 1.06
Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design. Adv Inorg Chem (2009) 1.01
Mediators of inflammation and the inflammatory process. J Allergy Clin Immunol (1999) 1.00
Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and leishmaniasis. Mini Rev Med Chem (2004) 0.97
New aspects on the role of lipoxygenases in cancer progression. Histol Histopathol (2005) 0.96
Purification of arachidonate 5-lipoxygenase from potato tubers. Methods Enzymol (1990) 0.94
Abietic acid inhibits lipoxygenase activity. Phytother Res (2002) 0.94
Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. Eur J Cancer (2002) 0.94
Nitric oxide as a chemical link in the generation of pain from veins in humans. Pain (1996) 0.87
The anti-apoptotic effect of leukotriene B4 in neutrophils: a role for phosphatidylinositol 3-kinase, extracellular signal-regulated kinase and Mcl-1. Cell Signal (2005) 0.86
Antiproliferative activity of chelating N,O- and N,N-ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds. Dalton Trans (2010) 0.82
Antinociceptive properties and nitric oxide synthase inhibitory action of new ruthenium complexes. Eur J Pharmacol (1999) 0.82
The antinociceptive activities of 1-(4-aryl-2-thiazolyl)-3,5-disubstituted-2 pyrazolines in mouse writhing test. J Pharm Pharm Sci (2004) 0.80
Novel mononuclear ruthenium(II) compounds in cancer therapy. Asian Pac J Cancer Prev (2012) 0.79
Antinociceptive effect of a ruthenium complex in mice. Auton Autacoid Pharmacol (2008) 0.78
Synthesis, potentiometric titration, electrochemical investigation and biological properties of trans-[RuCl2(dinic)4] (dinic = 3,5-pyridinecarboxylic acid). J Inorg Biochem (1999) 0.78
Synthesis of organometallic ruthenium(II) complexes with strong activity against several human cancer cell lines. J Inorg Biochem (2012) 0.78
Compared effects of ruthenium red and cis [Ru(NH3)4Cl2]Cl on the isolated ischaemic-reperfused rat heart. Fundam Clin Pharmacol (1995) 0.77
Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion. Int J Oncol (2004) 0.76
Synthesis, characterization, DNA-binding and cleavage studies of [Ru(bpy)2(actatp)]2+ and [Ru(phen)2(actatp)]2+ (actatp=acenaphthereno[1,2-b]-1,4,8,9-tetraazariphenylence). J Inorg Biochem (2003) 0.76
Spinal mediators of hyperalgesia. Drugs (1994) 0.76
HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem (2002) 4.91
LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem (2003) 3.97
Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide. Eur J Med Chem (2006) 3.79
Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett (2002) 3.56
Synthesis and antiviral activity evaluation of some new 6-substituted 3-(1-adamantyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles. Farmaco (2002) 2.47
Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther (2004) 2.45
Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev (2005) 2.24
Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. J Antimicrob Chemother (2005) 2.14
Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds. Eur J Med Chem (2006) 2.04
Synthesis and anti-hIV activity of 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substituted benzimidazoles. Farmaco (2002) 2.04
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 1.99
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties. Bioorg Med Chem Lett (2003) 1.97
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol (2005) 1.91
Influence of 2-substituent on the activity of imidazo[1,2-a] pyridine derivatives against human cytomegalovirus. Bioorg Med Chem (2002) 1.77
Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems. J Med Chem (2007) 1.76
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe (2011) 1.74
Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol (2003) 1.73
Synthesis and antiviral activity of new pyrazole and thiazole derivatives. Eur J Med Chem (2009) 1.71
Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Bioorg Med Chem (2006) 1.68
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur J Med Chem (2009) 1.64
In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J Virol (2003) 1.63
Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction. J Virol (2003) 1.61
Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother (2004) 1.60
Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. Eur J Med Chem (2007) 1.60
Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem (2010) 1.59
Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res (2002) 1.57
Synthesis, antibacterial, antifungal and antiviral activity evaluation of some new bis-Schiff bases of isatin and their derivatives. Molecules (2007) 1.55
CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS (2004) 1.55
In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother (2004) 1.54
Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol (2003) 1.54
Clinical features and treatment of adenovirus infections. Rev Med Virol (2008) 1.53
A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A (2002) 1.53
Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells. PLoS One (2011) 1.52
Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. J Med Chem (2002) 1.51
Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature (2005) 1.51
Selective inhibitors of picornavirus replication. Med Res Rev (2008) 1.50
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother (2008) 1.46
Antiviral therapy: quo vadis? Future Med Chem (2010) 1.44
Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds. Bioorg Med Chem (2004) 1.41
Hydantoin derivatives of L- and D-amino acids: synthesis and evaluation of their antiviral and antitumoral activity. Molecules (2006) 1.36
Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives. Eur J Med Chem (2008) 1.36
Design, synthesis, and biological evaluation of hybrid molecules containing alpha-methylene-gamma-butyrolactones and polypyrrole minor groove binders. J Med Chem (2004) 1.35
[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging (2003) 1.35
Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. Antiviral Res (2007) 1.33
Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res (2008) 1.31
Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc (2008) 1.29
Anti-influenza virus agents: synthesis and mode of action. Med Res Rev (2008) 1.28
Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS (2004) 1.28
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity. J Med Chem (2003) 1.28
Zinc(II) complexes of constrained antiviral macrocycles. Dalton Trans (2012) 1.28
3,5-Bis(benzylidene)-4-oxo-1-phosphonopiperidines and related diethyl esters: Potent cytotoxins with multi-drug-resistance reverting properties. ChemMedChem (2009) 1.27
Design and synthesis of bioactive adamantane spiro heterocycles. Bioorg Med Chem Lett (2007) 1.27
Synthesis and antiviral evaluation of benzimidazoles, quinoxalines and indoles from dehydroabietic acid. Bioorg Med Chem (2004) 1.26
The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med Res Rev (2006) 1.24
Deoxythreosyl phosphonate nucleosides as selective anti-HIV agents. J Am Chem Soc (2005) 1.24
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J Virol (2005) 1.24
Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int J Biochem Cell Biol (2008) 1.23
Aryloxy phosphoramidate triesters as pro-tides. Mini Rev Med Chem (2004) 1.23
The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev (2009) 1.22
Cytotoxic 5-aryl-1-(4-nitrophenyl)-3-oxo-1,4-pentadienes mounted on alicyclic scaffolds. Eur J Med Chem (2006) 1.21
Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J Virol (2006) 1.21
The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones. Eur J Med Chem (2008) 1.20
Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles. Bioorg Med Chem Lett (2002) 1.19
Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. Eur J Med Chem (2007) 1.19
Drug targets in cytomegalovirus infection. Infect Disord Drug Targets (2009) 1.17
Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir Ther (2007) 1.17
Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones. Bioorg Chem (2004) 1.17
Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J Virol (2004) 1.17
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity. J Med Chem (2002) 1.16
Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg Med Chem Lett (2007) 1.15
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs. Bioorg Med Chem (2008) 1.14
Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother (2005) 1.13
Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: a new class of pestivirus inhibitors. Bioorg Med Chem Lett (2006) 1.13
New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol (2002) 1.13
Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity. Eur J Med Chem (2007) 1.11
AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol (2005) 1.11
Configurationally restricted bismacrocyclic CXCR4 receptor antagonists. J Med Chem (2006) 1.10
Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides. J Med Chem (2005) 1.10